What is an apolipoprotein (Apo) laboratory test and what does it measure?

What is an Apolipoprotein (Apo) Laboratory Test?

Apolipoprotein (Apo) laboratory tests measure specific protein components of lipoproteins in the blood, with Apo B measuring the number of atherogenic (cholesterol-carrying) particles and Apo A-I measuring the major protein in HDL cholesterol. 1

Core Concepts

Apolipoprotein B (Apo B)

• Apo B is the primary structural protein found on all atherogenic lipoproteins, including LDL, VLDL, IDL, chylomicrons, and Lp(a), with each atherogenic particle containing exactly one Apo B molecule, making it a direct measure of the total number of cholesterol-carrying particles in the blood 2, 3
• Apo B is superior to LDL cholesterol for predicting cardiovascular risk because it counts particle number rather than cholesterol content—you can have normal LDL-C but still have many small, dense LDL particles (high Apo B), particularly in diabetes, metabolic syndrome, and hypertriglyceridemia 4, 3
• Normal Apo B levels are typically <100 mg/dL for high-risk patients and <80 mg/dL for very high-risk patients 1, 5
• An Apo B level ≥130 mg/dL is considered a significant risk-enhancing factor for atherosclerotic cardiovascular disease 1, 5

Apolipoprotein A-I (Apo A-I)

• Apo A-I is the major protein component of HDL cholesterol and plays a crucial role in reverse cholesterol transport, moving cholesterol from arteries back to the liver 6
• Unlike Apo B, Apo A-I measurement has minimal role in routine clinical practice because evidence for therapeutic interventions targeting Apo A-I elevation is weak 1
• The evidence base for lowering Apo B is substantially stronger than for raising Apo A-I, making Apo B reduction the primary therapeutic focus 1

Clinical Indications for Testing

When to Order Apo B Testing

The American College of Cardiology provides specific guidance on when Apo B testing adds clinical value:

• In adults aged 40-75 years with borderline (5-7.4%) or intermediate (7.5-19.9%) 10-year ASCVD risk, Apo B measurement may refine risk assessment and guide decisions on statin therapy initiation or intensification 1
• When triglycerides are persistently ≥200 mg/dL, Apo B is particularly valuable because LDL-C calculations become unreliable and may underestimate atherogenic particle burden 1, 4
• In patients with metabolic syndrome, diabetes, or chronic kidney disease, where discordance between LDL-C and actual atherogenic particle number is common 1, 4
• For monitoring treatment response in high-risk patients, with targets of <100 mg/dL for high-risk and <80 mg/dL for very high-risk patients 1

When NOT to Order Apo Testing

• The 2010 ACC/AHA guideline assigns a Class III (No Benefit) recommendation against measuring Apo B, Apo A-I, or the ApoB/ApoA-I ratio for cardiovascular risk assessment in asymptomatic adults without established coronary artery disease 1
• Do not order Apo A-I or the ApoB/ApoA-I ratio in routine risk assessment, as these provide little additional risk information beyond traditional lipid panels and lack evidence for improving clinical outcomes 1
• For routine assessment in asymptomatic adults, a standard fasting lipid profile (total cholesterol, LDL-C, HDL-C, triglycerides) is sufficient 1

Advantages Over Standard Lipid Testing

• Apo B directly counts atherogenic particles rather than estimating cholesterol content, providing more biologically meaningful information about cardiovascular risk 2, 3
• Apo B remains accurate when triglycerides are elevated (≥200 mg/dL), whereas calculated LDL-C becomes unreliable in this setting 1, 4
• Apo B better identifies residual cardiovascular risk in patients already on statin therapy who have achieved LDL-C targets but still have elevated particle numbers 2, 3
• In conditions like diabetes and metabolic syndrome where small, dense LDL particles predominate, Apo B reveals increased risk that LDL-C may miss 4, 3

Important Limitations and Caveats

• Apo B testing adds extra expense and inter-laboratory variability in measurement reliability compared to standard lipid panels 1
• Although observational studies suggest Apo B predicts coronary events better than standard lipids, prospective validation studies have not demonstrated improved clinical outcomes or risk reclassification when Apo B is added to routine care 1
• In patients with elevated Lp(a) (>30-50 mg/dL or >75-125 nmol/L), standard Apo B measurements may underestimate total cardiovascular risk because Lp(a) particles contain Apo B but have additional atherogenic properties 1
• The relationship between Apo A-I and HDL is less direct than that between Apo B and LDL, making Apo A-I a less reliable marker for cardiovascular risk 1
• Drug-induced increases in HDL/Apo A-I have not been shown to improve outcomes, making the ApoB/ApoA-I ratio a problematic treatment target 1

Practical Clinical Algorithm

For clinicians deciding whether to order apolipoprotein testing:

1. Start with a standard fasting lipid profile for all patients undergoing cardiovascular risk assessment 1

2. Consider adding Apo B measurement only in these specific scenarios:

   • Intermediate-risk patients (5-19.9% 10-year ASCVD risk) where the result would change management decisions 1
   • Persistent triglycerides ≥200 mg/dL where LDL-C calculation is unreliable 1
   • Metabolic syndrome, diabetes, or chronic kidney disease where particle number may be discordant with LDL-C 1

3. If Apo B ≥130 mg/dL, treat as a risk-enhancing factor and initiate or intensify statin therapy 1, 5

4. Do not routinely order Apo A-I or ApoB/ApoA-I ratio, as these lack evidence for improving clinical outcomes 1